英文【Chambers】医疗健康:医疗器械2025

CHAMBERS GLOBAL PRACTICE GUIDESHealthcare: Medical Devices 2025Definitive global law guides offering comparative analysis from top-ranked lawyersChina: Law & Practice Alan Zhou, Coco Fan and Kelly Cao Global Law OfficeCHINA2CHAMBERS.COMLaw and PracticeContributed by: Alan Zhou, Coco Fan and Kelly Cao Global Law OfficeContents1. Applicable Product Safety Regulatory Regimes p.41.1 Medical Devices p.41.2 Healthcare Products p.51.3 Medicines p.51.4 Technologies and Digital Health p.61.5 Borderline Products p.72. Commercialisation and Product Life Cycle p.82.1 Design and Manufacture p.82.2 Corporate Social Responsibility, the Environment and Sustainability p.102.3 Advertising and Product Claims p.102.4 Marketing and Sales p.122.5 Internationalisation p.152.6 Post-Marketing Obligations, Including Corrective Actions and Recalls p.163. Regulator Engagement and Enforcement p.173.1 Regulatory Authorities p.173.2 Regulatory Enforcement Mechanisms p.194. Liability p.194.1 Product Safety Offences p.194.2 Product Liability p.194.3 Judicial Requirements p.204.4 Costs p.204.5 Product-Related Contentious Matters p.204.6 Class Actions, Representative Actions or Co-Ordinated Proceedings p.214.7 ADR Mechanisms p.214.8 Interrelation Between Liability Mechanisms p.215. Applicable Product Safety Regulatory Regimes p.225.1 Policy Development p.225.2 Legislative Reform p.235.3 Impact of Artificial Intelligence p.23CHINA Law and PracticeContributed by: Alan Zhou, Coco Fan and Kelly Cao, Global Law Office 3CHAMBERS.COMGlobal Law Office dates back to the establishment of China’s Legal Consultant Office of the Council for the Promotion of International Trade in 1979. GLO has become one of the largest and leading Chinese law firms, with more than 500 lawyers practising in its Beijing, Shanghai, Shenzhen and Chengdu offices. Its life sciences and healthcare (L&H) practice group was one of the first in China and provides “one-stop” legal services for every area of the industry, including M&A, investment and funding, licence in and out, dai-ly operation, IP protection and advice on compliance, including internal and government investigations, anti-bribery matters and dispute settlement. Under a changing regulatory environment, GLO’s L&H team has the perfect combination of international experi-ence and local know-how to support various inno-vation and pilot projects, including digital healthcare and MAH/CMAH trial cases. The team participates extensively in the formulation of local codes of con-duct and benchmark policies/rules.AuthorsAlan Zhou is the leading partner of the L&H practice group at Global Law Office, and routinely represents multinational corporations, well-known Chinese state-owned and private enterprises, and private equity/venture capital funds in the L&H area. He has been engaged by local authorities and industrial associations to advise on legislation and industry standards in the L&H industry, including the formulation of the compliance guidelines for the h

立即下载
医药生物
2025-10-22
25页
1.07M
收藏
分享

英文【Chambers】医疗健康:医疗器械2025,点击即可下载。报告格式为PDF,大小1.07M,页数25页,欢迎下载。

本报告共25页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
本报告共25页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
水滴研报所有报告均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
相关图表
医药生物行业本月涨幅居前的个股图 28:医药生物行业本月跌幅居前的个股
医药生物
2025-10-22
来源:医药生物行业10月投资策略展望:关注ESMO数据发布及三季报业绩情况
查看原文
SW 医药生物、沪深 300 市盈率走势图 26:SW 医药生物相对沪深 300 的估值溢价率
医药生物
2025-10-22
来源:医药生物行业10月投资策略展望:关注ESMO数据发布及三季报业绩情况
查看原文
本月 SW 医药生物三级子行业涨跌幅
医药生物
2025-10-22
来源:医药生物行业10月投资策略展望:关注ESMO数据发布及三季报业绩情况
查看原文
年初至今 SW 医药生物子行业涨跌幅图 23:本月 SW 医药生物子行业涨跌幅
医药生物
2025-10-22
来源:医药生物行业10月投资策略展望:关注ESMO数据发布及三季报业绩情况
查看原文
天然牛黄、人工牛黄市场价
医药生物
2025-10-22
来源:医药生物行业10月投资策略展望:关注ESMO数据发布及三季报业绩情况
查看原文
7-ADCA、硫氰酸红霉素市场价
医药生物
2025-10-22
来源:医药生物行业10月投资策略展望:关注ESMO数据发布及三季报业绩情况
查看原文
回顶部
报告群
公众号
小程序
在线客服
收起